Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Blumel

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of the Advanced Practitioner in Oncology|June 26, 2015
Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesSusan Blumel, Jackie Broadway-Duren
Clinical Journal of Oncology Nursing|October 10, 2008
Bendamustine: a novel cytotoxic agent for hematologic malignanciesSusan Blumel, Amy Goodrich, Cheryl Martin, et al.
Clinical Journal of Oncology Nursing|March 9, 2005
Patient-specific vaccine therapy for non-Hodgkin lymphomaMaribeth Hohenstein, Susan E King, Jennifer M Fiore, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypesOwen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of the Advanced Practitioner in Oncology|June 26, 2015
Approaches to Managing Safety With Lenalidomide in Hematologic MalignanciesSusan Blumel, Jackie Broadway-Duren
Clinical Journal of Oncology Nursing|October 10, 2008
Bendamustine: a novel cytotoxic agent for hematologic malignanciesSusan Blumel, Amy Goodrich, Cheryl Martin, et al.
Clinical Journal of Oncology Nursing|March 9, 2005
Patient-specific vaccine therapy for non-Hodgkin lymphomaMaribeth Hohenstein, Susan E King, Jennifer M Fiore, et al.
Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.
British Journal of Haematology|February 18, 2009
Patients with chemotherapy-refractory mantle cell lymphoma experience high response rates and identical progression-free survivals compared with patients with relapsed disease following treatment with single agent bortezomib: results of a multicentre Phase 2 clinical trialOwen A O'Connor, Craig Moskowitz, Carol Portlock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 14, 2010
Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypesOwen A O'Connor, Carol Portlock, Craig Moskowitz, et al.
Pageof 1